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Цель. Изучение влияния приема препаратов магния на концентрацию матриксных металлопротеи-
наз и ионов магния у пациентов с варикозной болезнью вен нижних конечностей.
Материал и методы. В исследование включено 124 пациента с варикозной болезнью вен нижних 
конечностей (ВБВНК) классов С2-С6, которых разделили на 4 группы. В I-й группе проводили опера-
тивное лечение с последующим назначением стандартного консервативного лечения (32 человека); во 
II-й группе после операции в дополнение к консервативному лечению назначали препараты магния (32 
человека); в III-й группе проводили консервативное лечение без операции (30 человек); в IV-й группе 
пациенты получали стандартное консервативное лечение и препараты магния (30 человек). V-ю кон-
трольную группу составили 20 здоровых добровольцев, не страдающих варикозной болезнью. Пациентам 
II-й и IV-й групп назначали магния оротат 500 мг 2 табл. 3 раза в день в течение 3 мес. Содержание в сы-
воротке крови матриксной металлопротеиназы-1 (ММП-1), матриксной металлопротеиназы-9 (ММП-9), 
тканевого ингибитора матриксной металлопротеиназы-1 (ТИМП-1) определяли методом количественно-
го твердофазного иммуноферментного анализа. Концентрацию ионов магния определяли колориметри-
ческим методом. 
Результаты. У пациентов с ВБВНК отмечался достоверно меньший уровень магния по сравнению с 
условно здоровыми добровольцами, не страдающими варикозной болезнью: 35,5% среди страдающих ва-
рикозной болезнью имели дефицит магния, в то время как всего 15% имели снижение данного показателя 
среди здоровых добровольцев. На фоне проводимой дополнительной терапии препаратами магния, отмеча-
лось уменьшение количества пациентов с дефицитом магния в группах с ВБВНК, снижение концентрации 
ММП-9 и повышение активности ТИМП-1.
Заключение. Исследование подтвердило эффективность применения препаратов магния, которые 
обладают выраженным влиянием на процессы деградации коллагена и внеклеточного матрикса, снижают 
активность ММП-9, повышают концентрацию ТИМП-1, тем самым влияя на баланс ММП/ТИМП у па-
циентов с ВБВНК.
Ключевые слова: первичное варикозное расширение вен, фармакотерапия, магний, матриксные металло-
протеиназы, дисплазия соединительной ткани
Objective. To study the effect of magnesium drugs on the concentration of matrix metalloproteinases and 
magnesium ions in patients with varicose veins of the lower extremities.
Methods. The study included 124 patients with varicose veins of the lower extremities, C2-C6, which were 
divided into 4 groups. In the 1st group, surgical treatment followed with the administering the standard conservative 
treatment (32 patient); in the 2nd group after the operation in addition to conservative treatment, magnesium drugs 
(32 patient) were prescribed; in the 3rd group, conservative treatment without surgery (30 patient) was performed; 
in the 4th group patients received standard conservative treatment and magnesium drugs (30 patient). The 5th 
control group consisted of 20 healthy volunteers who did not suffer from varicose veins disease. Patients of groups 
2 and 4 were given magnesium orotate 500 mg 2 tablets 3 times a day for 3 months. The content of serum matrix 
metalloproteinase-1 (MMP-1), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of matrix metalloproteinase-1 
(TIMP-1) was determined by quantitative solid-phase enzyme immunoassay. The magnesium ion concentration was 
determined by colorimetric method. 
Results. In patients with varicose veins of lower extremities a significantly lower level of magnesium was 
registered compared to healthy volunteers not suffering from varicose veins: 35.5% of those with varicose veins 
had a magnesium deficiency, while only 15% had a decrease in this indicator among healthy volunteers. Against 
the background of additional therapy with magnesium drugs, there was a decrease in the number of patients with 
magnesium deficiency in groups with varicose veins of lower extremities, a decrease in MMP-9 concentration and 
an increase in TIMP-1 activity was also established.
Conclusions. This study has confirmed the efficacy of magnesium drugs which have a pronounced effect on 
collagen degradation processes and extracellular matrix, reduce the activity of MMP-9, increase the concentration 




Varicose veins of the lower extremities are one 
of the most common diseases of peripheral vessels 
[1, 2, 3]. According to leading Russian phlebologists, 
more than 35 million people suffer from chronic 
venous insufficiency (CVI), which develops against 
the background of varicose veins, 15% of them have 
complicated forms of the disease [4].
Despite the successes achieved in the treat-
ment and diagnosis of patients with varicose veins, 
many unsolved problems still remain, both theo-
retical and practical. We have to state that still 
much remains unclear in etiology and pathogenesis 
of varicose veins, which, in fact, is represented 
by a certain set of risk factors, the priority and 
significance of which may be different [5]. 
Several years ago, the idea about the par-
ticipation of special matrix enzymes – metallo-
proteinases in the development of varicose veins 
of the subcutaneous veins was stated for the first 
time. Metalloproteinases play an important role in 
the development of such physiological processes 
as morphogenesis, resorption, tissue remodeling, 
angiogenesis. The function of metalloproteinases 
consists in the degradation of various protein 
components of the intercellular matrix (collagen, 
elastin, fibronectin, glycosaminoglycan) and, in 
general, in maintaining its homeostasis. In the 
preservation of metalloproteinases in a latent 
form and preventing their excessive activation, 
tissue inhibitors of metalloproteinases play an 
important role. Among them, the tissue inhibi-
tor metalloproteinases-1 (TIMP-1) regulates the 
activity of matrix metalloproteinase-1 (MMP-1) 
and matrix metalloproteinase-9 (MMP-9) in the 
body. For the normal course of the processes 
of the extracellular matrix reorganization, it is 
necessary to maintain an equilibrium between 
the activity of metalloproteinases and their in-
hibitors [6, 7].
Also, according to modern concepts, vari-
cose veins are a group of hereditary diseases that 
are directly related to a violation of synthesis or 
degradation of fibrous connective tissue structures 
that occur in the embryonic and postnatal periods 
of life. Understanding the role of magnesium in 
maintaining the structure of connective tissue is 
inseparable from the molecular-cellular structure of 
connective tissue. Magnesium is a universal regu-
lator of biochemical and physiological processes 
in the body: it participates in energy, plastic and 
electrolyte metabolism [8, 9]. Magnesium as a 
physiological factor in synthesis of collagen is of 
particular interest.
Experiments on animals confirm the effect of 
magnesium on the biological activity of MMP. In 
mice with artificially induced magnesium deficien-
cy, there is a significant thinning of the aortic wall 
compared to control animals. The specific colora-
tion of the two main types of fibers (collagen and 
elastin) has shown significant structural changes in 
both components. These changes correlated with 
an increase in the total activity of matrix metal-
loproteinases MMP-2 and MMP-9 [10]. 
The data given above suggest that the Mg2+ 
deficiency should probably lead to an increase 
in MMP activity, which begin to destroy the 
structural components of the extracellular matrix 
(ECM) (primarily collagen) at a higher rate, and 
also affect the tissue inhibitors of matrix metal-
loproteinases. 
Objective. To study the effect of magnesium 
drugs on the concentration of matrix metallo-
proteinases and magnesium ions in patients with 
varicose veins of the lower extremities.
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What this paper adds
A complex biochemical assessment of markers of connective tissue dysplasia (magnesium ions, matrix 
metalloproteinases, tissue inhibitor of matrix metalloproteinases) in patients with varicose veins has been performed. 
An analysis of the effect of magnesium drugs in the treatment of this pathology has been conducted. The expediency 
of using magnesium drugs in patients with varicose veins, including those who underwent phlebectomy, has been 
confirmed from the position of their influence on the level of matrix metalloproteinases and their inhibitors.
Научная новизна статьи
Произведена комплексная биохимическая оценка маркеров дисплазии соединительной ткани (ионов 
магния, матриксных металлопротеиназ, тканевого ингибитора матриксных металлопротеиназ) у пациентов 
с варикозной болезнью нижних конечностей. Проведен анализ влияния препаратов магния в лечении дан-
ной патологии. Подтверждена целесообразность применения препаратов магния у пациентов с варикозной 
болезнью, в том числе и у перенесших флебэктомию, с позиции влияния их на уровень матриксных ме-
таллопротеиназ и их ингибиторов.
Keywords: primary varicose veins, pharmacotherapy, magnesium, matrix metalloproteinase, connective tissue 
dysplasia
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Methods
The study included 124 patients with varicose 
veins, C2-C6, which were divided into 4 groups. In 
the 1st group, surgical treatment followed with the 
administering the standard conservative treatment 
(32 patient); in the 2nd group after the operation 
in addition to conservative treatment, magnesium 
drugs (32 patient) were prescribed; in the 3rd group, 
conservative treatment without surgery (30 patient) 
was performed; in the 4th group patients received 
standard conservative treatment and magnesium 
drugs (30 patient). The 5th control group consisted 
of 20 healthy volunteers who did not suffer from 
varicose veins. Patients of groups 2 and 4 were given 
magnesium orotate 500 mg 2 tablets 3 times a day 
for 3 months. The study was not of an interven-
tion nature, the choice of the treatment option was 
determined by the attending physician, taking into 
account the capabilities and desires of a patient.
The study was approved by the ethical com-
mittee of the Ryazan State Medical University 
named after Academician I.P. Pavlov.
The groups were comparable by sex, age, 
concomitant diseases, clinical class and duration of 
the disease. The distribution of patients by group, 
sex and age is presented in Table 1.
The criterion for inclusion in the study of 
patients of groups I-IV was clinically and in-
strumentally verified varicose veins of the lower 
extremities, in the control group – the absence 
of varicose veins. Exclusion criteria were previous 
thrombophlebitis of the superficial veins of the 
lower limbs; deep vein thrombosis of the lower 
limbs; obliterating diseases of the aorta, peripheral 
artery disease of the pelvis and lower limbs; coro-
nary artery disease, acute impairment of cerebral 
circulation in the anamnesis; diabetes; operations 
and manipulations on the superficial veins of the 
lower limbs; infectious-inflammatory diseases of 
soft tissues of the lower limbs. The study was ap-
proved by a local ethics committee and all patients 
signed the informed consent to participate in the 
study.
The samples of peripheral blood taken in the 
morning on an empty stomach were examined. The 
serum levels of MMP-9, MMP-1, and TIMP-1 
were determined by quantitative solid-phase enzyme 
immunoassay method using enzyme immunoassay 
kit for quantitative in vitro detection of matrix 
metalloproteinases in serum, blood plasma and 
other biological fluids, as well as cell lysates and 
supernatant of cell cultures (AbFrontier human 
MMP-1 ELISA, China, Bender MedSystems hu-
man MMP-9 ELISA, USA; Bender MedSystems 
human TIMP-9 ELISA, USA).
The concentration of Mg2+ was determined by 
photocolorimetric method using the "MAGNIUM-
OLVEX" kit (Olvex-Diagnosticum, Russia). Blood 
sampling for determining the level of biochemical 
markers was carried out at the beginning of the 
study and subsequently 1, 3 and 6 months after 
the start of treatment in patients with conservative 
and operative groups with varicose veins.
Statistics
The determination of the mean values, the 
standard deviation and the error of the arithmetic 
mean was made. To compare the values in the 
groups, the Student's t-test was used. For the con-
fidence level, the probability of a difference of 95% 
was accepted (p<0.05). To compare independent 
groups by qualitative characteristics, the Pearson's 
chi-squared test χ2 was used.
Results
According to WHO recommendations, the 
normal content of magnesium in serum is:
Table 1
The distribution of patients by group, sex and age
Groups N Clinical case (CEAP)  Age,  years 
 (М±σ)
Disease duration,  
(М±σ)
Sex (abs.  /%)
Males Females
I.  32 C2-C3 – 18 patient (56.25%)
C4 – 6 patient (18.75%)
C5-C6 – 8 patient (25%)
41.1±7.2 10.1±3.2 13 (40.6%) 19 (59.4%)
II.  32 C2-C3 – 18 patient (56.25%)
C4 – 6 patient (18.75%)
C5-C6 – 8 patient (25%)
45.2±9.3 11.1±2.7 14 (43.8%) 18 (56.2%)
III.  30 C2-C3 – 18 patient (60%)
C4 – 5 patient (16.7%)
C5-C6 – 7 patient (23.3%)
48.7±8.7 7.6±1.5 13 (43.3%) 17 (56.7%)
IV.   30 C2-C3 – 18 patient (60%)
C4 – 5 patient (16.7%)
C5-C6 – 7 patient (23.3%)
43.1±9.4 7.2±4.3 12 (40%) 18 (60%)
V.  20 – 44.1±6.2 – 8 (40%) 12 (60%)
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• from 0.74 to 1.15 mmol/L for children,
• from 0.75 to 1.26 mmol/L for adults,
• from 0.8 to 1.05 mmol/L for pregnant 
women.
At the same time, 0.5-0.74 mmol/L testifies 
to moderate magnesium deficiency in the body, 
and a level below 0.5 mmol/L – to a pronounced 
deficiency of magnesium ions.
Blood samples of patients with varicose veins 
and patients of the control group were taken as 
initial biochemical indices. The following results 
were obtained. In patients with varicose veins be-
fore the start of treatment in 64.5% of cases (80 
people) normal values of Mg2+ were observed. In 
35 people (28.2%) there was a moderate decrease 
in magnesium concentration. And a pronounced 
deficit was observed in the remaining 9 patients 
(7.3%). In the control group, only three people 
had a deficiency of magnesium (15%) (Fig. 1).
Further, against the background of the 
therapy, a significant decrease in the number of 
patients with magnesium deficiency in the second 
and fourth groups after 1 month of therapy was 
registered (p<0.05), and this indicator remained 
low throughout the study. While in the first and 
third groups throughout the study, the number of 
patients with magnesium deficiency remained at 
the initial level (Table 2).
Fig. 1. Distribution of patients with magnesium deficiency in groups. 
Δ – significant difference from groups of patients with varicose veins at the stage of screening (р <0.05).
Fig. 2. The concentration of MMP-9 in patients with varicose 
veins and the control group at the stage of inclusion in the study. 
Δ – significant difference from groups of patients with varicose veins at the stage of screening (р<0.05).
Table 2
Dynamics of changes in the number of patients with magnesium deficiency
Note: * – significant difference from the initial level (р<0.05).  Δ  – Significant difference from groups of patients with varicose 
veins at the stage of screening (р<0.05).
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Groups Number  of patients with magnesium deficiency (Mg2+<0,75 mmol/L)
V0 V1 (after  1 month) V2 (after  3 months) V3 (after  6 months)
I.  37.5% (12 people) 34.4% (11 people) 34.4% (11 people) 34.4% (11 people)
II.  31.3% (10  people) 9.4%*  (3 people) 3.1%*  (1 person) 3.1%*  (1 person)
III.  33.3% (10  people) 33.3% (10  people) 33.3% (10  people) 36.7% (11 people)
IV.    40% (12 people) 10  %*  (3 people) 0%*  (0  people) 3.3 %*  (1 person)
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Fig. 3. The concentration of MMP-1 in patients with varicose 
veins and the control group at the stage of inclusion in the study. 
Δ – significant difference from groups of patients with varicose veins at the stage of screening (р<0.05).
Table 3
The concentration of MMP-9 in patients of different groups (M±m)
In the control group, the concentration of 
MMP-9 was 4.5±1.32 ng/ml. In groups of patients 
with varicose veins, a significantly lower MMP-9 
level was found in comparison with the control 
group (11.3±4.86 ng/ml, p <0.05) (Fig. 2).
One month later, the concentration of MMP-
9 in the first group was 12.2±2.2 ng/ml, which was 
statistically significantly different from the baseline. 
The same value was noted in patients of the third 
group. In the second and fourth group, the indices 
were 6.2±0.8 ng/ml and 8.7±1.1 ng/ml, which was 
a significant decrease compared to the initial level 
of MMP-9 in these groups (p <0.05).
Three months later, there was a tendency to 
decrease MMP-9 concentration in the second 
and fourth groups (5.4±2.1 ng/ml and 8.0±1.4 
ng/ml, respectively). In the first and third groups, 
the MMP-9 index was kept at the initial level. In 
the I and III groups, MMP-9 indices did not dif-
fer significantly during the entire 6-month study 
period (Table 3).
In the control group, the concentration of 
MMP-1 was 4.8±0.73 ng/ml. In groups of patients 
with varicose veins, a significantly higher MMP-1 
level was found in comparison with the control 
group (6.9±1.16 ng/ml, p<0.05) (Fig. 3).
A month later, all groups showed a tendency to 
decrease in MMP-1 concentration in comparison 
with the initial level (p <0.05). The MMP-1 index in 
the first group was 5.4±0.5 ng/ml, in the second – 
6.1±0.4 ng/ml, in the third – 5.7±0.3 ng/ml, in 
the fourth – 5.8±0.6 ng/ml. Three months later, 
the trend towards a decrease in MMP-1 concentra-
tion in all four groups remained. Six months later, 
MMP-1 in all groups did not significantly differ 
statistically from the results that we received at the 
stage of patient inclusion (Table 4).
In patients with varicose veins, a higher level 
of TIMP-1 was observed than in the control group 
(210.8±21.1 ng/ml and 154.4±14.4 ng/ml, respec-
tively, p<0.05) (Fig. 4).
After one month of observation, the con-
centration of TIMP-1 in the first group was 
216.5±12.4 ng/ml, in the third - 212.3±13.2 ng/
ml, which statistically significantly did not differ 
from the initial index. While in the second and 
fourth group the indices were 274.3±18.9 ng/ml 
and 280.5±14.3 ng/ml, which was a significant 
increase in comparison with the initial level of 
TIMP-1 in these groups (p <0.05).
Three months later, there was a tendency for 
an increase in the concentration of TIMP-1 in the 
second and fourth groups (285.5±13.2 ng/ml and 
288.1±12.9 ng/ml, respectively). In the I and III 
Note: * – significant difference from the initial level (р<0.05).  ** – the differences are insignificant compared to the initial level (р 
















I. Surgery II. Surgery + Mg2+  III. Conservative 
treatment (CT)
IV.  CT + Mg2+  V. Control
The concentration of MMP-1 ng/ml 
Groups V0  
ng/ml
V1 (after  1 month)
ng/ml 
V2 (after  3 months)
ng/ml
V3 (after  6 months)
ng/ml
I.  11.3±1.7 12.2±2.2** 11.5±1.4** 11.2±1.9**
II.  10.1±1.3 6.2±0.8* 5.4±2.1* 5.5±2.1*
III.  12.7±2.5 12.2±1.3** 11.7±2.2** 11.4±2.4**
IV.   11.6±2.1 8.7±1.1* 8.0±1.4* 7.6±0.9*
V.  4.5±1.3˂ – – –
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Fig. 4. The concentration of TIMP-1 in patients with varicose veins 
and the control group at the stage of inclusion in the study.











I. Surgery II. Surgery + Mg2+  III. Conservative 
treatment (CT)
IV.  CT + Mg2+  V. Control
The concentration of TIMP-1 ng/ml 
groups, TIMP-1 values did not differ significantly 
throughout the 6-month study period (Table 5).
Discussion
For the first time, a complex biochemical 
evaluation of magnesium ions, matrix metallo-
proteinases, and tissue inhibitor of matrix met-
alloproteinases was carried out in patients with 
varicose disease of the lower limbs. The analysis 
of magnesium preparations effect in the treatment 
of this pathology was also performed.
In patients with varicose veins, a significantly 
lower magnesium level was observed compared to 
conditionally healthy volunteers who did not suf-
fer from varicose veins (patients with a magnesium 
deficiency of 35.5% and 15%, respectively, p<0.05), 
indicating the presence of connective tissue dyspla-
sia (DCT) in patients with varicose veins.
Against the background of additional therapy 
with magnesium drugs (magnesium orotate), there 
was a decrease in the number of patients with 
magnesium deficiency in groups of patients with 
varicose veins, which created favorable prerequi-
sites for the further course of the disease from the 
position of connective tissue dysplasia.
There was also a significant (p<0.05) decrease in 
MMP-9 activity in patients of Group II and Group 
IV after 1 month of therapy, and it was reduced 
during 6 months. The concentration of TIMP-1 in 
these groups increased on the contrary and remained 
elevated against the background of magnesium 
Table 5
The concentration of TIMP-1 in patients of different groups (M±m)
Note:  *  – significant difference from the initial level (р <  0.05).  **  – the differences are insignificant compared to the initial level 
(р > 0.05). Δ – significant difference from groups of patients with varicose veins at the stage of screening (р<0.05).
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Table 4
The concentration of MMP-1 in patients of different groups (M±m)
Note:  *  – significant difference from the initial level (р<0.05).  **  – the differences are insignificant compared to the initial level 
(р>0.05). Δ – Significant difference from groups of patients with varicose veins (р<0.05).
Groups V0  
ng/ml
V1 (after  1 month)
ng/ml
V2 (after  3 months)
ng/ml
V3 (after  6 months)
ng/ml
I.  6.7±0.4 5.4±0.5* 5.2±0.8* 6.3±0.9**
II.  7.5±0.7 6.1±0.4* 6.2±0.5* 7.0±0.7**
III.  6.5±0.5 5.7±0.3* 5.3±0.5* 6.2±0.4** 
IV.   6.9±0.4 5.8±0.6* 5.9±0.4* 6.4±0.5**
V.  4.8±1.3˂ – – –
Groups V0  
ng/ml
V1 (after  1 month)
ng/ml
V2 (after  3 months)
ng/ml
V3 (after  6 months)
ng/ml
I.  211.3±11.5 216.5±12.4** 207.2±10.3** 208.3±11.2** 
II.  207.6±9.4 274.3±18.9* 285.5±13.2* 291.2±11.3* 
III.  218.4±21.4 212.3±13.2** 205.4±9.5** 215.6±14.5** 
IV.   214.3±7.7 280.5±14.3* 288.1±12.9* 275.2±11.9* 
V.  154.4±14.4 ˂ – – –
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therapy. In the 1st and 3rd groups, the differences 
in MMP-9 and TIMP-1 concentrations were not 
observed during the follow-up period in comparison 
with the initial index. Taking into consideration the 
intake of magnesium drugs in the second and fourth 
groups of patients, one can judge about the influ-
ence of magnesium ions on the decrease of MMP-9 
activity, thereby inhibiting the extracellular matrix 
degradation and collagen destruction processes. The 
most pronounced decrease was noted in the second 
group, where the patients were treated surgically in 
addition to conservative therapy.
There is a significant (p<0.05) decrease in 
MMP-1 activity in patients with varicose veins 
after 1 and 3 months of the therapy. Taking into 
account the intake of magnesium drugs in the sec-
ond and fourth groups of patients, it can be judged 
that magnesium ions did not affect the activity of 
MMP-1, and the decrease in the indices is likely 
due to the effect of standard therapy for patients 
with varicose veins.
Conclusions
One has revealed the elevated levels of MMP-1, 
MMP-9 and TIMP-1 in the blood and a decrease in 
magnesium concentration in patients with varicose 
veins of the lower extremities in comparison with 
the control group, people without varicose veins.
There is a decrease in MMP-1 concentration 
during varicose veins treatment during 3 months of 
active therapy, both in operative and in conserva-
tive treatment groups, this indicator comes to the 
baseline level after 6 months.
Magnesium drugs reduce the activity of MMP-
9 and increase the concentration of TIMP-1, 
thereby affecting the balance of MMP / TIMP in 
patients with varicose veins of the lower extremities.
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